title: Zidovudine-induced fever.
abstract: Zidovudine (3'-azido-3'deoxythymidine, AZT, Retrovir) is the first antiretroviral drug to demonstrate clinical efficacy for symptomatic human immunodeficiency virus infection. In a large, placebo-controlled trial, nausea and hematologic toxicity, but not fever, occurred more frequently in zidovudine- than in placebo-treated patients. However, in an open label study, fever severe enough to halt zidovudine administration occurred in 10% of 70 acquired immune deficiency syndrome (AIDS) patients receiving the drug. We now describe three AIDS patients with severe zidovudine-induced fever in whom other causes of fever were excluded. Zidovudine-induced fever was confirmed in each case by drug rechallenge. Using an enzyme immunoassay, we detected IgM antibodies directed against a zidovudine-serum protein conformational determinant in one of these three patients. Neither IgG nor IgM anti-zidovudine antibodies were present in sera from the other two patients with zidovudine fever, from four AIDS patients who discontinued zidovudine for reasons other than fever, or from five AIDS patients who never received zidovudine. Zidovudine may cause fever as a severe adverse effect in patients with AIDS. Either type III or type IV hypersensitivity may mediate this reaction.
authors.affiliation: Department of Medicine, University of California San Francisco.
authors.forename: M A
authors.initials: MA
authors.lastname: Jacobson
authors.forename: M S
authors.initials: MS
authors.lastname: McGrath
authors.forename: P
authors.initials: P
authors.lastname: Joseph
authors.forename: J B
authors.initials: JB
authors.lastname: Molaghan
authors.forename: S
authors.initials: S
authors.lastname: Tadepalli
authors.forename: R
authors.initials: R
authors.lastname: Quinn
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D000328:Adult; D000906:Antibodies / Q000032:analysis; D000936:Antigen-Antibody Complex / Q000032:analysis; D003166:Complement Activating Enzymes; D003172:Complement C1; D015922:Complement C1q; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D007124:Immunoenzyme Techniques; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008297:Male; D015215:Zidovudine / Q000009:adverse effects* / Q000276:immunology
chemical_list: D000906:Antibodies; D000936:Antigen-Antibody Complex; D003172:Complement C1; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D015215:Zidovudine; D015922:Complement C1q; D003166:Complement Activating Enzymes